Physician profile
James E Sapp
NPI 1013647882
$3,475.21
in general payments reported to CMS, 2019-2025
30 companies · $70.01 in 2025
The $70.01 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $390 · 2023: $1,702 · 2024: $1,313 · 2025: $70.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $536.64 | 2022-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $450.12 | 2022-2025 | Mounjaro, Emgality, Zepbound |
| Abbvie INC. | $420.60 | 2023-2024 | |
| Novo Nordisk INC | $364.20 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.41 | 2022-2024 | Farxiga, Breztri |
| Lundbeck LLC | $191.30 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $183.96 | 2022-2024 | Trintellix |
| Glaxosmithkline, LLC. | $109.45 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $106.55 | 2023-2024 | |
| Amgen INC. | $79.22 | 2023-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $78.08 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.50 | 2022-2024 | |
| Exact Sciences Corporation | $67.50 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $64.71 | 2024 | Qelbree |
| Corium, LLC | $61.28 | 2023 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $58.82 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.47 | 2022-2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.20 | 2023-2025 | Jardiance, Tradjenta |
| Idorsia Pharmaceuticals US INC | $41.79 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $40.82 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $27.90 | 2023 | Verquvo, Belsomra, Gardasil 9 |
| Boston Scientific Corporation | $27.64 | 2024 | Watchman Access System |
| Avanir Pharmaceuticals, INC. | $23.78 | 2022 | |
| Dexcom, INC. | $23.34 | 2024 | Dexcom G6 Transmitter |
| Medicomp INC | $23.09 | 2024 | Telepatch Cardiac Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.55 | 2024 | Xifaxan |
| Philips North America LLC | $18.13 | 2024 | (Ck6) Holter |
| Esperion Therapeutics, INC. | $16.76 | 2023 | Nexletol |
| Edwards Lifesciences Corporation | $15.79 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ardelyx, INC. | $14.61 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.